ภาวะกล้ามเนื้อหัวใจอักเสบที่เกิดจากวัคซีนโควิด 19 ชนิดเอ็มอาร์เอ็นเอ

Pimpan  Sapkham

Authors

Pimpan Sapkham Dararassamee Hospital, Mae Rim, Chiang Mai, 50180, Thailand

Keywords:

mRNA COVID-19 vaccine, myocarditis

Abstract

The Messenger Ribonucleic acid (mRNA) vaccine is the most effective type of vaccine against COVID-19 infection, demonstrating over 90% efficacy in preventing COVID-19 infection and reducing the severity and mortality of the disease. It is recommended for use in the population aged 12 years and older. The most concerning adverse event after mRNA vaccination is myocarditis. Although the mechanism of myocarditis after vaccination is still unknown, it is primarily observed in males younger than 30 years old, often related to the second dose of vaccine, and consistently occurring within 3 to 7 days. Common symptoms include chest pain, shortness of breath, and sensations of
a fast, fluttering, or pounding heart. Adverse events are rare; however, heart failure and shock occur in severe cases. Cardiac MRI may show irregular EKG and Cardiac enzyme is abnormal. Most myocarditis cases are completely reversible. Compared with the advantages of mRNA vaccination against COVID-19 infection, it is recommended. However, individuals at a high risk of myocarditis should consult medical professionals to assess the risk-benefit ratio before vaccination.

Downloads

Download data is not yet available.

References

Center for Disease Control and Prevention. (2023). Myocarditis and pericarditis after mRNA COVID-19 vaccination. Retrieved from https://www.CenterforDiseaseControlandPrevention.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html

Department of Disease Control. (2021). Guidelines for COVID-19 vaccination in the outbreak situation in 2021 in Thailand, 1st revised edition. Retrieved from https://tmc.or.th/covid19/download/pdf/covid-19-public-Vaccine-040664.pdf

Department of Disease Control. (2023). Weekly COVID-19 patient situation within the country. Retrieved from https://ddc.moph.go.th/covid19-dashboard/

Expert Panel on Adverse Events Following Vaccination Thai Cardiology Association under the Bureau of Epidemiology, Department of Disease Control. (2021). Myocarditis and pericarditis after mRNA vaccination. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Retrieved from https://www.dropbox.com/s/cuxgk4348rwjnnz/Vaccine%20induced%20myocarditis_Jul29_2021_Final_v2.pdf?dl=0&fbclid=IwAR2xPffHZ-bGjBIOBBJfuA4vL5Yh0XYzAwJZkS3EHT2qrLakEM27bCOm2_Y

Heidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., . . . Lüscher, T. F. (2022). Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. European Journal of Heart Failure, 24(11), 2000–2018. https://doi.org/10.1002/ejhf.2669

Ling, R. R., Ramanathan, K., Tan, F. L., Tai, B. C., Somani, J., Fisher, D., & MacLaren, G. (2022). Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis. The Lancet, Respiratory Medicine, 10(7), 679–688. https://doi.org/10.1016/S2213-2600(22)00059-5

Straus, W., Urdaneta, V., Esposito, D.B., Mansi, J. A., Rodriguez, C. S., Burton, P., & Vega, J. M. (2021). Myocarditis after mRNA-1273 vaccination: A population-based analysis of 151 million vaccine recipients worldwide. Clinical Infectious Disease, 70(3), e544-e552. https://doi.org/10.1093/cid/ciac446

Su, J. R. (2021). Myopericarditis following COVID-19 vaccination: Updates from the vaccine adverse event reporting system (VAERS). Retrieved from https://stacks.cdc.gov/view/cdc/109492

Thitichai, P., & Taweewiyakarn, P. (2021). Report on the results of reviewing the COVID-19 disease situation and preventive control measures at the global level and in Thailand. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Retrieved from http://www.thaincd.com/document/file/download/knowledge/COVID19.65.pdf

Wongrachit, K. (Ed.). (2022). Endemic approach to COVID-19. Strategy and Planning Division, Office of Permanent Secretary.

World Health Organization. (2023). Coronavirus disease (COVID-19) pandemic. Retrieved from https://www.WorldHealthOrganization.int/emergencies/diseases/novel-coronavirus-2019